This article first appeared on GuruFocus. Novo Nordisk (NVO, Financials), is exploring the hair-loss market as the Ozempic and Wegovy maker looks to diversify beyond its blockbuster GLP-1 drugs. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart Chief Scientific Officer Martin Lange said Novo could leverage its scientific expertise to move into hair loss, although the company has not decided whether to pursue the market first. The comments came as Novo outlined plans to find new growth areas beyond its weight-loss franchise.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.